Yusheng Zhang

Yusheng Zhang

Auto-generated profile, based on publicly available information

Yusheng Zhang

Department of Pharmacy, Guangdong Medical University, No. 1, Xincheng Dadao, Songshan Lake Science and Technology Industry Park, Dongguan, 523808, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2018 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
YZY. S. Zhang
Y. S. Zhang
WWW. Y. Weng
W. Y. Weng
BXBaocheng Xie
Baocheng Xie
YMY. Meng
Y. Meng
YHY. H. Hao
Y. H. Hao
ZZZhikun Zhou
Zhikun Zhou

24 May 2018 in Stem Cells International
Verified
Journal Article
Open access
PDF file
BXBaocheng Xie
Baocheng Xie
HLHou-Long Luo
Hou-Long Luo
YZYusheng Zhang
Yusheng Zhang
QWQinghui Wang
Qinghui Wang
CZChenhui Zhou
Chenhui Zhou
DXDaohua Xu
Daohua Xu
Objective. Critical limb ischemia (CLI) is the most dangerous stage of peripheral artery disease (PAD). Many basic researches and clinical treatment had been focused on stem cell transplantation for CLI. This systematic review was performed to review evidence for safety and efficacy of autologous stem cell therapy in CLI. Methods. A systematic literature search was performed in the SinoMed, PubMed, Embase, ClinicalTrials.gov, and Cochrane Controlled Trials Register databases from building database to January 2018. Results. Meta-analysis showed that cell therapy significantly increased the probability of ulcer healing (RR = 1.73, 95% CI = 1.45–2.06), angiogenesis (RR = 5.91, 95% CI = 2.49–14.02), and reduced the amputation rates (RR = 0.59, 95% CI = 0.46–0.76). Ankle-brachial index (ABI) (MD = 0.13, 95% CI = 0.11–0.15), TcO2 (MD = 12.22, 95% CI = 5.03–19.41), and pain-free walking distance (MD = 144.84, 95% CI = 53.03–236.66) were significantly better in the cell therapy group than in the control group (P<0.01). Conclusions. The results of this meta-analysis indicate that autologous stem cell therapy is safe and effective in CLI. However, higher quality and larger RCTs are required for further investigation to support clinical application of stem cell transplantation.